AbbVie マネジメント

マネジメント基準チェック /14

AbbVieの CEO はRobert Michaelで、 Jul2024年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 14.44Mで、 9.9%給与と90.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.006%を直接所有しており、その価値は€ 18.45M 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と11.8年です。

主要情報

Robert Michael

最高経営責任者

US$14.4m

報酬総額

CEO給与比率	9.9%
CEO在任期間	less than a year
CEOの所有権	0.006%
経営陣の平均在職期間	1.1yrs
取締役会の平均在任期間	11.8yrs

経営陣の近況

Recent updates

CEO報酬分析

AbbVie の収益と比較して、Robert Michael の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$5b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$14m	US$1m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$10m	US$1m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$12m	US$1m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$13m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$9m	US$907k	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$3m	US$554k	US$6b

報酬と市場: Robertの総報酬 ($USD 14.44M ) は、 German市場 ($USD 5.20M ) の同規模の企業の平均を上回っています。

報酬と収益: Robertの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Robert Michael (54 yo)

less than a year

在職期間

US$14,441,320

報酬

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 72.8m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 18.4m
Scott Reents	Executive VP & CFO	2.4yrs	US$10.19m	0.00087% € 2.9m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.011% € 37.5m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% € 11.7m
Roopal Thakkar	Executive VP of Research and Development & Chief Scientific Officer	less than a year	データなし	0.00093% € 3.1m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	データなし	データなし
Perry Siatis	Executive VP	2.1yrs	データなし	0% € 0
Sanjay Narayan	Senior VP	1.1yrs	データなし	データなし
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% € 2.6m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	1.1yrs	データなし	データなし
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.8yrs	データなし	0.0032% € 10.4m

1.1yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 4AB0の経営陣は経験豊富とはみなされません ( 1.1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 72.8m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 18.4m
Roxanne Austin	Lead Independent Director	11.8yrs	US$388.39k	0.00065% € 2.1m
Thomas Freyman	Independent Director	4.5yrs	US$389.98k	0.0071% € 23.4m
Glenn Tilton	Independent Director	11.8yrs	US$421.58k	0.0014% € 4.7m
Edward Rapp	Independent Director	11.8yrs	US$394.98k	0.00091% € 3.0m
William H. Burnside	Independent Director	11.8yrs	US$377.48k	0% € 0
Frederick Waddell	Independent Director	11.8yrs	US$369.98k	0.00011% € 363.6k
Melody Meyer	Independent Director	7.5yrs	US$369.98k	0% € 0
Brett Hart	Independent Director	8.8yrs	US$384.98k	0% € 0
Rebecca Roberts	Independent Director	6.5yrs	US$359.98k	データなし
Robert Alpern	Independent Director	11.8yrs	US$461.18k	0.000010% € 33.1k

11.8yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: 4AB0の取締役会は経験豊富で経験豊富です ( 11.8年の平均在任期間)。

AbbVie マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Announces Board Changes

AbbVie Inc. Announces Board of Directors Changes

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie Inc. Announces Chief Executive Officer Changes

Recent updates

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14